Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2011-12-06
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S199000
Reexamination Certificate
active
08071623
ABSTRACT:
The present invention relates to compounds of formula I:and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and/or radiosensitizers for cancer treatment.
REFERENCES:
patent: 6100283 (2000-08-01), Griffin et al.
patent: 6310082 (2001-10-01), Griffin et al.
patent: 6448271 (2002-09-01), Lubisch
patent: 6509365 (2003-01-01), Lubisch
patent: 6696437 (2004-02-01), Lubisch
patent: 6737421 (2004-05-01), Lubisch
patent: 7041675 (2006-05-01), Lubisch
patent: 7087637 (2006-08-01), Grandel
patent: 2006/0063926 (2006-03-01), Ma et al.
patent: 2006/0229289 (2006-10-01), Zhu et al.
patent: 2006/0229351 (2006-10-01), Zhu et al.
patent: 2007/0112047 (2007-05-01), Penning et al.
patent: 2007/0259937 (2007-11-01), Giranda et al.
patent: 2009/0062268 (2009-03-01), Chu
patent: 2009/0197863 (2009-08-01), Chu et al.
patent: 2009/0275619 (2009-11-01), Boueres et al.
patent: 2349227 (2008-02-01), None
patent: 0 879 820 (2001-12-01), None
patent: WO97/04771 (1997-02-01), None
patent: WO 99/59973 (1999-11-01), None
patent: 200026193 (2000-05-01), None
patent: WO00/26192 (2000-05-01), None
patent: WO00/29384 (2000-05-01), None
patent: WO00/32579 (2000-06-01), None
patent: WO00/64878 (2000-11-01), None
patent: WO00/68206 (2000-11-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO01/57038 (2001-08-01), None
patent: WO01/85687 (2001-11-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO03/007959 (2003-01-01), None
patent: WO 03/062234 (2003-07-01), None
patent: WO 03/106430 (2003-12-01), None
patent: WO 2004/014861 (2004-02-01), None
patent: WO2005/066136 (2005-07-01), None
patent: WO2007/041357 (2007-04-01), None
patent: 2007113596 (2007-10-01), None
Grever et al. “National cancer inst . . . ” Seminar in Oncology 19(6) 622-638 (1992).
Cancer Classification p. 1-3 (2005) internet.
Bouerer et al. “Preparation of amide . . . ” CA 148:448784 (2007).
Huw D. Thomas, et al., Molecular Cancer Research, vol. 6 (3), pp. 945-956 (2007).
Office Action mailed Oct. 10, 2010 for U.S. Appl. No. 12/225,857, (2010).
Boueres, J. et al., Preparation of amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose) polymerase (part) inhibitors, Caplus 147:448784 (2007).
Categories of Cancer/ Cancer Classification, pp. 1-3; http://training.seer.cancer.gov/modules—...ase/unit3—categories2—by—histology.html, (2005).
Grever, M. et al., “The National Cancer Institute: Cancer Drug Discovery and Development Program”, Seminars in Oncology, 19(6):622-638 (Dec. 1992).
Horig H., et al., “From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference”, Journal of Translational Medicine, 2:44-51 (Dec. 20, 2004).
Lord, C. et al., “Targeted therapy for cancer using PARP inhibitors”, Current Opinion in Pharmacology, 8:363-369 (2008).
Rouleau, M. et al., “PARP inhibition: PARP1 and beyond”, Nature Reviews/Cancer, 10:293-301 (Apr. 2010).
Schafer, S. et al., “Failure is an option: learning from unsuccessful proof-of-concept trials”, Drug Discovery Today, 13(21/22):913-916 (Nov. 2008).
Underhill, C . et al., “A review of PARP inhibitors: from bench to bedside”, Annals of Oncology Advance Access, Published Jul. 19, 2010, pp. 1-12; doi:10.1093/annonc/mdq322.
Jones Philip
Ontoria Ontoria Jesus Maria
Scarpelli Rita
Schultz-Fademrecht Carsten
Chang Celia
Instituto di Ricerche di Biologia Molecolare P. Angeletti SpA
Leff Matthew A.
Muthard David A.
LandOfFree
Amide substituted indazoles as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide substituted indazoles as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide substituted indazoles as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262451